Chardan Capital Reaffirms “Buy” Rating for Coya Therapeutics (NASDAQ:COYA)

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reiterated by research analysts at Chardan Capital in a research report issued on Thursday,Benzinga reports. They presently have a $14.00 price target on the stock. Chardan Capital’s price target would suggest a potential upside of 109.58% from the company’s current price.

Separately, D. Boral Capital restated a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a research note on Tuesday.

Coya Therapeutics Stock Performance

Shares of COYA stock opened at $6.68 on Thursday. Coya Therapeutics has a fifty-two week low of $4.75 and a fifty-two week high of $10.24. The stock has a 50 day simple moving average of $6.33 and a two-hundred day simple moving average of $6.49. The company has a market cap of $111.60 million, a P/E ratio of -10.28 and a beta of 0.31.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.14. The firm had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.10 million. On average, research analysts predict that Coya Therapeutics will post -1.15 earnings per share for the current year.

Institutional Investors Weigh In On Coya Therapeutics

Several large investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its position in Coya Therapeutics by 3.3% in the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after buying an additional 4,485 shares during the last quarter. Newbridge Financial Services Group Inc. purchased a new stake in Coya Therapeutics in the 4th quarter worth about $401,000. CM Management LLC raised its stake in Coya Therapeutics by 11.1% in the 4th quarter. CM Management LLC now owns 160,000 shares of the company’s stock valued at $917,000 after acquiring an additional 15,941 shares during the period. Jane Street Group LLC purchased a new stake in Coya Therapeutics during the fourth quarter valued at about $74,000. Finally, Northern Trust Corp lifted its holdings in Coya Therapeutics by 12.2% during the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock valued at $164,000 after purchasing an additional 3,099 shares during the last quarter. Hedge funds and other institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.